MHC class I molecules on CD4 T cells regulate receptor-mediated activation signals

Acute rejection correlates with expression of major histocompatibility complex class I antigens on peripheral blood CD3(+)CD8(+) T-lymphocytes following skin transplantation in mice

This study investigated major histocompatibility complex class I (MHC-I) antigen expression on peripheral blood T-cells after transplantation to assess its potential as an early marker of acute graft rejection (AGR). Using a mouse model with or without immunosuppressive treatment, the expression of MHC-I antigens on CD3(+)CD8(+) T-lymphocytes was assessed by flow cytometry following syngeneic graft (n = 138) or allograft (n = 138) skin transplantation. The occurrence of AGR was assessed by examining the degree of lymphocyte and monocyte infiltration in transplant biopsies. During AGR, expression of MHC-I antigens increased significantly compared with pre-transplant levels in the allograft group, even with immunosuppressive treatment. The highest expression of MHC-I antigens occurred 5 - 6 days before macroscopic rejection. These results suggest that expression of MHC-I antigens on peripheral blood CD3(+)CD8(+) T-lymphocytes could be used as an early marker for predicting AGR.

The amount of surface HLA-I on T lymphocytes decreases in breast infiltrating ductal carcinoma patients

Human leucocyte antigen class I (HLA-I), which includes HLA-A, -B and -C, is an essential immune factor participating in the antitumour immune response. The changes in HLA-I expression in peripheral blood T lymphocytes in cancer patients have yet to be defined. This study examined the expression of HLA-I on CD4(+) and CD8(+) T lymphocytes in female patients with stage I - IV breast infiltrating ductal carcinoma, benign breast tumour diseases (mammary intraductal papilloma or breast fibroadenoma), and in healthy controls. HLA-I was down-regulated on CD4(+) T lymphocytes from patients with stage III and IV cancer, and on CD8(+) T lymphocytes in patients with stage I - IV cancer compared with healthy controls. HLA-I expression in T lymphocytes may contribute towards immune-balance disorders in tumour patients.

Effect of dexamethasone on B7 regulation and T cell activation in neonates and adults

The safety of dexamethasone for neonates has been questioned, partly because of its multiple unspecific effects on the immune system. Specific effects of dexamethasone on co-stimulatory and immune suppressive functions of neonatal compared with adult macrophages (MPhi) are not known. We evaluated the effect of dexamethasone on the expression and regulation of MPhi B7 family receptors (B7-1, CD80; B7-2, CD86) and on their ability to co-stimulate T cells. Cord blood macrophages (CBMPhi) and MPhi from healthy adults (PBMPhi) were isolated, and cell surface markers were phenotyped by flow cytometry. In tissue culture, cells were exposed to dexamethasone, interferon-gamma (IFN-gamma), cAMP, or a T cell mitogen (alphaCD3) and examined for their capacity to activate or destroy T cells. CBMPhi were less able to up-regulate CD80 and CD86 than PBMPhi (p < 0.05). Dexamethasone inhibited the up-regulation of CD80, CD86, and HLA-DR on PBMPhi and even more so on CBMPhi (p < 0.05 versus PBMPhi for CD80 and CD86). In the presence of dexamethasone, stimulation with alphaCD3 MAb enhanced cytotoxic functions of PMBMPhi and CB(mu)phi with an increase in deleted T cells, a reduced fraction of enlarged T cells, and an inhibition of T cell CD28 up-regulation, which again were more pronounced with CBMPhi (p < 0.05 versus PBMPhi). In conclusion, neonatal MPhi are exquisitely sensitive to the inhibitory effects of dexamethasone on B7 expression. Although perhaps producing the desired therapeutic effect, dexamethasone may do so in newborns at the expense of a near complete paralysis of MPhi-dependent T cell function.